Integrated Diagnostics Holdings Stock EBITDA
| IDHC Stock | 0.44 0.01 2.22% |
Integrated Diagnostics Holdings fundamentals help investors to digest information that contributes to Integrated Diagnostics' financial success or failures. It also enables traders to predict the movement of Integrated Stock. The fundamental analysis module provides a way to measure Integrated Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integrated Diagnostics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 1.3 B | 951.5 M |
Integrated | EBITDA |
Integrated Diagnostics Holdings Company EBITDA Analysis
Integrated Diagnostics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Integrated Diagnostics EBITDA | 1.28 B |
Most of Integrated Diagnostics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integrated Diagnostics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Integrated Ebitda
Ebitda |
|
According to the company disclosure, Integrated Diagnostics Holdings reported earnings before interest,tax, depreciation and amortization of 1.28 B. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The ebitda for all United Kingdom stocks is notably lower than that of the firm.
Integrated EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integrated Diagnostics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Integrated Diagnostics could also be used in its relative valuation, which is a method of valuing Integrated Diagnostics by comparing valuation metrics of similar companies.Integrated Diagnostics is currently under evaluation in ebitda category among its peers.
Integrated Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0969 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 261.19 M | ||||
| Shares Outstanding | 581.33 M | ||||
| Shares Owned By Insiders | 33.97 % | ||||
| Shares Owned By Institutions | 42.29 % | ||||
| Price To Book | 4.77 X | ||||
| Price To Sales | 0.06 X | ||||
| Revenue | 4.12 B | ||||
| Gross Profit | 2.8 B | ||||
| EBITDA | 1.28 B | ||||
| Net Income | 737.36 M | ||||
| Total Debt | 1.18 B | ||||
| Book Value Per Share | 4.64 X | ||||
| Cash Flow From Operations | 543.66 M | ||||
| Earnings Per Share | 0.03 X | ||||
| Target Price | 0.54 | ||||
| Number Of Employees | 6.69 K | ||||
| Beta | 0.45 | ||||
| Market Capitalization | 26.16 B | ||||
| Total Asset | 5.77 B | ||||
| Retained Earnings | 1.28 B | ||||
| Working Capital | 686.94 M | ||||
| Net Asset | 5.77 B |
About Integrated Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Integrated Diagnostics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integrated Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integrated Diagnostics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Integrated Stock Analysis
When running Integrated Diagnostics' price analysis, check to measure Integrated Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Diagnostics is operating at the current time. Most of Integrated Diagnostics' value examination focuses on studying past and present price action to predict the probability of Integrated Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integrated Diagnostics' price. Additionally, you may evaluate how the addition of Integrated Diagnostics to your portfolios can decrease your overall portfolio volatility.